Global Lipid Nanoparticles CDMO Market to have Rapid Growth - Explore Top Market Companies

 

Integration of LNPs in the fight against COVID-19, a rich pipeline of LNP-related drugs, and private equity investments in lipid nanoparticles CDMOs are some of the primary drivers driving the worldwide lipid nanoparticles CDMO market.

Lipid nanoparticles are lipid-based nanoparticles. These are spherical vesicles composed of ionizable lipids and lipid nanoparticles that play an important role in the protection and transport of mRNA to cells. It has risen as a potential vehicle for delivering a number of medicines in recent years.

Acceptance of Lipid Nanoparticles (LNPs) in the Fight Against COVID-19 Promotes Lipid Nanoparticle Growth CDMO Market

Lipids are substances that are critical for mRNA-based treatments since they serve as the basis for living cells. A lipid nanoparticle (LNP) made of specific lipids surrounds the mRNA. The LNP safeguards the mRNA and delivers it into the cell, where it is released. Because of their versatility, LNPs are today recognized as the most advanced medicine delivery technology and have gained global acceptance in the fight against COVID-19.

“The effectiveness of mRNA vaccines against COVID-19 boosted the demand for lipid nanoparticle (LNP)-mediated drug delivery for RNA vaccines and therapeutics. As projects entered the commercialization stage from the clinical trial stage, developers were more challenged to ensure consistency in LNP formulation as the necessary quantities increased.” - Senior Scientist, Lipid Nanoparticle CDMO, USA

A Significant pipeline of drugs related to lipid nanoparticles (LNP) drives demand for lipid nanoparticles CDMOs.

LNPs can transport unstable genetic materials such as mRNA and gene therapies into cells while protecting them. Around 2,000 LNP-related pipeline drugs are now being developed throughout the world. The need for pharmaceutical contract manufacturing for clinical trials and commercial mass production is predicted to grow in the coming years. Top market players are rapidly implementing aggressive expansion strategies to access the worldwide lipid nanoparticles CDMO market, citing LNPs' huge development potential.

  • In May 2023, Inventage Lab signed a co-development and manufacturing (CDMO) commercialization agreement with EuBiologics for LNP production.

Funding by private equity firms in lipid nanoparticle CDMOs drive the growth of the lipid nanoparticle CDMO market

Many private equity firms have increased their investments in Lipid Nanoparticles CDMOs, citing the attractive development potential of the global lipid nanoparticles CDMO market.

  • In June 2023, Vernal Biosciences, an mRNA and LNP Contract CDMO announcedthat it had completed a $20MM funding round led by Ampersand Capital Partners and Charles River Labs, with participation from Dynamk Capital and the Vermont Center for Emerging Technologies, to expand its GMP mRNA and LNP manufacturing capabilities.
  • In August 2022, Ampersand Capital Partners, a private equity firm specialized in growth equity investments in the healthcare business, announced a majority recapitalization of Phosphorex, a drug delivery-focused CDMO that provides microspheres and polymer and lipid nanoparticles.

Competitive Landscape Analysis: Lipid Nanoparticles CDMO Market

Evonik Health Care, Merck, CordenPharma, Phosphorex, eTheRNA Manufacturing, Fujifilm Pharmaceuticals, Helix Biotech, BIOVECTRA, Vernal Biosciences, and others are among the well-established and upcoming companies in the lipid nanoparticles CDMO market.

Key Market Players Adopt Aggressive Growth Strategies to Establish Their Foothold in the Lipid Nanoparticles CDMO Market

To get a bigger market share, key players in the global lipid nanoparticles CDMO market are pursuing aggressive expansion tactics such as increasing production capacities, acquiring connected businesses, and entering into agreements or partnerships with related firms.

For instance,

  • In March 2023, Evonik open new facilities in Lafayette, Indiana, in the United States and Hanau, Germany for pharmaceutical lipids.
  • In March 2022, CordenPharma increased its lipid manufacturing capacity to support mRNA vaccines.
The global lipid nanoparticles CDMO market is expected to expand in the future years as a result of the expanding application scope of lipid nanoparticles in vaccines, cancer treatments, gene therapy products, and aggressive expansion tactics employed by global market participants.

Explore the Comprehensive and Detailed Research Report on Lipid Nanoparticles CDMO Market at https://meditechinsights.com/lipid-nanoparticles-cdmo-market/

Comments

Post a Comment

Popular posts from this blog

The Transplantation Market Anticipated to Expand with 9-10% CAGR by 2029 as Need for Organ Transplants Rises

Image
  The market is propelled by various factors, including advancements in medical technology, the rising prevalence of chronic diseases that lead to organ failure, increasing awareness of transplantation as a viable treatment option, and evolving regulatory and reimbursement policies. In medical terms, transplantation refers to the surgical procedure of transferring cells, tissues, or organs from a donor to a recipient to replace malfunctioning or damaged body parts. Its primary goal is to restore normal function or improve the quality of life for the recipient. Transplantation is often used to treat end-stage organ failure, severe injuries, certain cancers, and congenital defects that are not manageable through other medical treatments. This specialized field requires careful matching of donors and recipients, advanced surgical techniques, and comprehensive post-transplant care to ensure success. Types of transplantation include: Kidney Transplantation: Involves replacing a fail...
Read more

Global MedTech CMO Market to Witness a Robust Annual Growth Rate of 11%.

Image
  Due to increased outsourcing by OEMs and higher growth rates in segments like Drug delivery and MIS (Minimally Invasive Surgery). Additionally, the growing burden of chronic diseases, the rising demand for cost-effective medical devices and the increasing complexity of regulatory requirements, further drives the MedTech CMO market. The MedTech CMO (Contract Manufacturing Organization) market involves outsourcing the manufacturing of medical devices and equipment to specialized third-party organizations. Get A Free PDF Sample of Our Research Report : https://meditechinsights.com/medtech-cmo-market/request-sample/ The Strategic Benefits Fueling MedTech Companies' Shift to CMO Services The decision to engage Contract Manufacturing Organization (CMO) services is primarily driven by the need to reduce costs and improve operational efficiency. CMOs provide substantial cost advantages, enabling medical device companies to reduce capital expenditure on manufacturing infrastructure and l...
Read more

The Fluoroscopy Equipment Market Grows Steadily, Anticipated to Achieve a CAGR of 5-7%

Image
  Key Drivers of Market Growth: Technological Advancements, Chronic Disease Incidence, and Aging Demographics Recent innovations in fluoroscopy, such as digital imaging, dose reduction methods, and multimodal integration, have significantly improved image quality, patient safety, and procedural efficiency. The rise in chronic conditions like cardiovascular disease, gastrointestinal issues, and orthopedic ailments underscores the need for advanced imaging solutions like fluoroscopy, which aids in diagnosing and treating these conditions. Furthermore, the aging global population has led to an increased need for diagnostic imaging to manage age-related health issues, and the use of fluoroscopy in minimally invasive procedures in specialties such as cardiology, orthopedics, oncology, and urology is expanding. Increased healthcare spending, paired with the evolution of medical technology and favorable reimbursement policies, is further driving the adoption of fluoroscopy equipment world...
Read more